CVRx rises after FDA clears expanded label for heart implant device

CVRx

26/12/2023 15:30

** Shares of medical device maker CVRx  CVRX.O  rise 13.1%
to $28.51, their highest since 2021 IPO levels 
    ** Co says the U.S. FDA has approved a revised label for its
heart implant device Barostim to include data from a
post-marketing study 
    ** The U.S. annual market opportunity for Barostim is now
$2.2 billion, or 76,000 new patients, as compared to the co's
earlier estimate of $1.4 billion, or 55,000 new patients - CVRX 
  
    ** Including session's gain, stock up 53.3% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))